Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, how much of the £20 billion in funding for research and development announced in the Autumn Budget and Spending Review 2021 will be allocated to new Tuberculosis treatments and vaccines.

BEIS published its funding allocations for UK Research and Innovation (UKRI) in May 2022. The total UKRI allocation as published was £25.1 billion for 2022-25, providing UKRI and its constituent councils with the funding needed to deliver world class research and innovation.

UKRI funds a range of research programmes and activities focussed on respiratory diseases. Over a recent 5-year period (2016-17 to 2020-21), UKRI’s Medical Research Council spent over £155.6 million on research relevant to respiratory health and disease. This figure includes over £45 million spent on research specifically relevant to Tuberculosis. Figures do not include spend on research relating to Covid-19.